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rEsuMo
os vectores lipídicos apresentam inúmeras vantagens para a administração oral de substâncias farmacológicas, p.ex. 
são compostos por moléculas lipídicas semelhantes àquelas que figuram nos tecidos humanos, tornando-se bio-
compatíveis, biotoleráveis e biodegradáveis. são exemplos as tradicionais emulsões o/A, as suspensões de nanopar-
tículas lipídicas (slns e nlcs) e, recentemente, as solemuls®, que permitem localizar fármacos fracamente solúveis 
em ambas as fases das emulsões, na camada interfacial de lecitina. este artigo aborda o papel dos lípidos no aumento 
da absorção e da biodisponibilidade de fármacos administrados oralmente.
PALAVRAS-ChAVE: administração oral de fármacos; lipossomas; nanopartículas de lípidos sólidos; vectores lipídicos 
nanoestruturados.
abstraCt
lipid carriers show several advantages for oral delivery of pharmacologically active drugs, e.g. are composed of lipid 
molecules similar to those in human tissues, becoming therefore biocompatible, biotolerable and biodegradable. 
examples include traditional o/w emulsions, suspensions of lipid nanoparticles (slns and nlcs) and, recently, the 
solemuls®, which allows localizing poorly soluble drug molecules both in oil and aqueous phases, in the interfacial 
layer of lecithin. this paper reports on the role of lipids in enhancing both drug absorption and bioavailability when 
administered orally.
KEy-WORDS: oral drug delivery; liposomes; solid lipid nanoparticles; nanostructured lipid carriers.
194 1. introduction
Administration of drugs through the oral route is usually the most acceptable way of self-medication due 
to both enhanced patients convenience and compliance. nevertheless, drug absorption through the 
gastrointestinal tract (git) is deeply hampered by different biological barriers (biochemical and/or physi-
cal), of which the first pass metabolism occurring both in enterocytes and in liver is but a good example 
(lennernäs, 1998). biochemical barriers include enzymes existing in the gastrointestinal (gi) lumen as well 
as efflux pumps present in the epithelial cells, whereas physical barriers consist of epithelial cell membra-
nes, tight junctions and mucus layer. overcoming these barriers is currently one of the most challenging 
goals in oral drug delivery (majumdar and mitra, 2006; leonard et al., 2006; Hamman et al., 2005; ghilzai, 
2004). many drug molecules cannot be effectively and efficiently delivered orally in their original form due 
to several factors, viz. instability, low membrane permeability, poor solubility and efflux transport mecha-
nisms (merisko-liversidge, 2002). thus, several strategies have been developed aiming at improving drug 
bioavailability following oral administration (morishita and peppas, 2006; Hamman et al., 2007). some of 
those strategies include maximizing the intestinal uptake of drug molecules while others focus on pro-
tecting the drug molecules from degradation, but combinations thereof have also been reported (goyal 
et al., 2005; Hamman et al., 2007). With their ability to solubilize hydrophobic drug molecules, lipid-based 
drug delivery systems have proven to improve drug absorption and dissolution rates in the git. parenteral 
oil-in-water (o/w) emulsions are used as intravenous (i.v.) carriers for poorly water-soluble drug molecules, 
which are carried in the inner oil phase. this strategy allows ‘solubilisation’ of such water-insoluble drugs 
without using organic solvents and avoids at the same time the use of solubilisers potentially having 
side effects (crauste-manciet et al., 1998). compared to other particulate carriers such as liposomes and 
polymeric nanoparticles, o/w emulsions possess several advantages: they integrate accepted excipients; 
are physically long-term stable; can be produced on large scale using existing production lines; and can 
be sterilised by autoclaving. However, despite these manifold advantages, there are only a small number 
of drugs on the market formulated as i.v. emulsions, and two major reasons account for this: (i) poor solu-
bility of drug molecules in regulatory accepted (grAs – generally recognized As safe) oils, and (ii) poor 
solubility of drug molecules in water and simultaneously in oils in general.
2. drug aBsorPtion tHrougH tHe gastrointestinal tract
Following oral administration, a drug passes sequentially the mouth, esophagus, stomach, duodenum, 
jejunum (small intestine), colon (large intestine) and finally leaves the body if not absorbed. the first re-
quirement for absorption to occur is drug dissolution, i.e. only dissolved drugs have the ability to perme-
ate the gi membrane. As a result, drug solubility is a parameter of paramount importance. in the upper 
part of the intestine, duodenum, the bile released by the gallbladder may enhance the in vivo solubility 
of drugs to a large extent (Wiedmann and Kamel, 2002; bakatselou et al., 1991; Horter and Dressman, 
1997). once dissolved, the drug is available in the intestine to be promptly absorbed. in order to facilitate 
the efficient absorption of nutrients from the intestinal lumen, the available surface area of the intesti-
ne is very large; the small intestine is invaginated and contains villi, with additional surface area being 
provided via the microvilli present on the apical side of the enterocytes (intestinal absorptive cells). the 
enterocytes are covered by mucus and an unstirred (quiescent) water layer. the biological membrane 
of enterocytes, consisting of a bilayer of phospholipids (ppl) integrating other structures and molecules 
such as proteins, cholesterol, carbohydrates, fatty acids, acylglycerols, etc. (lee, 2003; mcconnell and ra-
dhakrishnan, 2003), presents the main barrier for absorption. As ppl (amphiphilic in nature) are the most 
abundant biomolecules in the lipid membrane and possess specific physicochemical properties, they 
will dictate the required characteristics of drugs in order to permeate through the double ppl bilayer. if 
ppl were much more hydrophilic, the membrane would be unstable and simply dissolve in water. on 
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phase to form membranes. A drug molecule may pass through the layer of enterocytes in many different 
ways, but passive diffusion is the most important one. besides passive diffusion, other mechanisms to 
reach systemic circulation include facilitated diffusion, paracellular transport, and endocytosis (Duizer, 
1999). prior to reaching systemic circulation, the drug molecule may be metabolized during absorption 
by enzymes existing in the enterocytes. Furthermore, when the drug reaches the portal vein it will direc-
tly be delivered to the liver where further metabolism may also take place. After passage through the li-
ver, the drug finally reaches systemic circulation and is duly carried by the blood towards specific targets. 
bioavailability is usually defined as the relative amount of an administered drug dose that reaches the 
systemic circulation (jantratid et al., 2008). before a drug is able to pass through a physiological barrier 
it must be in a dissolved state (ruckenstein and shulgin, 2005). important parameters that affect drug 
absorption and thus its bioavailability through the git include: (i) solubility and ionization state of drug 
in the lipids, (ii) aqueous solubility of drug required to provide an appropriate concentration gradient, 
(iii) oral dosage form, i.e. the drug release profile and dissolution rate, (iv) git motility, (v) blood flow and 
eventual pathological changes, (vi) gut microflora, which may metabolize some drugs, and (vii) presen-
ce of food and/or other medicines in the git. the following sections describe several state-of-the-art 
approaches to increase drug bioavailability following oral administration, by means of liposomes, lipid 
nanoparticles and, quite recently, by means of the so-called solemuls® technology.
3. liPid-Based carriers for oral drug delivery
3.1. lIposoMEs
liposomes have been one of the most extensively investigated colloidal carriers in particular to improve 
the therapeutics of potent drugs (samad et al., 2007; goyal et al., 2005), and can be used to control reten-
tion of entrapped drugs in the presence of biological fluids and enhanced vesicle uptake by target cells 
(goyal et al., 2005). liposomes are lyotropic liquid crystals (because they form liquid crystal phases due to 
the addition of a solvent) (Decher and ringsdorf, 1993) composed of relatively biocompatible and biode-
gradable materials. they consist of an aqueous core entrapped by one or more bilayers of natural (ppl) 
and/or synthetic lipids, which may differ in dimensions, composition, surface charge and structure (samad 
et al., 2007; goyal et al., 2005). Drugs with widely varying lipophilicities can be encapsulated in liposomes 
either in the ppl bilayer, in the entrapped aqueous core or at the bilayer interface. besides their ability to 
entrap hydrophilic and hydrophobic drug molecules, liposomes composed of natural lipids display highly 
interesting advantages by being biodegradable, biotolerable between their components and the human 
tissues, biologically inert, weakly immunogenic, produce no antigenic or pyrogenic reactions and reveal 
limited intrinsic toxicity (Decher and ringsdorf, 1993; goyal et al., 2005). liposomes are also easy to prepare, 
and their composition can be varied (e.g. including cholesterol molecules, cationic ppl) to obtain more 
efficient formulations (goyal et al., 2005; Zhang et al., 1997), and to inhibit rapid clearance of liposomes 
by controlling particle size, charge and surface hydration (mohammed et al., 2006). With respect to oral 
administration, liposome formulations are targeted to reduce toxicity, enhance bioavailability and increase 
accumulation at the target site (iwanaga et al., 1997; mcAlister et al., 1999; taira et al., 2004; lee et al., 2005). 
the latest developments in this field include (i) specific binding properties of a drug-carrying liposome to a 
target cell such as a tumour cell and specific molecules in the body (antibodies, proteins, peptides); and (ii) 
stealth liposomes, which are being especially employed as carriers for hydrophilic anticancer drugs like do-
xorubicin and mitoxantrone (samad et al., 2007). liposomes display a quite low physicochemical stability 
and in most cases require liophilization of the product to achieve proper stability during shelf-life. moreo-
ver, chemically labile drugs (e.g. peptides and proteins) suffer a relatively fast release when entrapped into 
liposomes, and thus, no controlled release is achieved.
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lipid nanoparticles (ln) are colloidal-sized carrier systems that have been developed at the beginning 
of the nineties to overcome some of the drawbacks pointed out for liposomes (muller et al., 2000; souto 
and muller, 2007). ln can also be composed of ppl, which are used as surfactants surfacing the nano-
particles and stabilizing them in aqueous dispersions. ln are characterized by a solid matrix revealing 
high physicochemical stability, including the possibility to achieve controlled release and also protec-
tion of chemically labile drugs entrapped within their matrix. the literature reports two types of ln, 
the solid lipid nanoparticles (sln) and the nanostructured lipid carriers (nlc). sln consist of a matrix 
composed of a lipid being solid both at room and body temperatures, which is covered by a surfactant 
film that stabilizes them in aqueous dispersions. With regard to nlc, these are produced by mixing solid 
lipids with liquid lipids in nlc, instead of highly purified lipids with relatively similar molecules in sln. 
this mixture has to be solid at least at 40ºc. the major difference between sln and nlc lies in the fact 
that production of the latter is performed by nanostructuring the lipid matrix, in order to increase drug 
loading and to prevent its leakage, giving more flexibility for modulation of drug release. the result is a 
less ordered lipid matrix with many imperfections, which can accommodate a higher amount of drug. 
regarding oral protein delivery, an ideal formulation should allow an enhanced drug bioavailability with 
low blood profile variations, and simultaneously avoiding plasma peaks (muller et al., 2006, 2008). the-
se systems can be alternative carriers for peptides, proteins and antigens (Almeida and souto, 2007). 
proteins and antigens intended for oral drug therapy can be entrapped within, or adsorbed onto the 
surface of ln. several advantages may be pointed out, such as improved protein stability, avoidance 
of proteolytic degradation, and sustained release. examples of peptides that have been successfully 
entrapped in ln are cyclosporine A (muller et al., 2006, 2008; ugazio et al., 2002; varia et al., 2008; Hu et al., 
2004), insulin (iwanaga et al., 1997; Zhang et al., 2006a,b), and calcitonin (garcia-Fuentes et al., 2005a,b). 
immunisation with protein antigens, infectious disease treatment, chronic diseases and cancer therapy 
might also be promising application areas for these carriers (Almeida and souto, 2007). the therapeutic 
efficacy of anti-Hiv agents (e.g. nucleoside and nucleotide analogues) is often hampered by poor bioa-
vailability and lack of drug penetration in infected target tissues and cells (li and chan, 1999; Hillaireau 
et al., 2006). However, the need of high doses due to the rapid elimination of these compounds, to their 
poor activation, and/or to their nonspecific distribution, often leads to side effects and resistances. ln 
have been demonstrated as potential carriers for antiviral nucleoside analogues, especially for anti-Hiv 
agents, regarding both intravenous and oral routes (li and chan, 1999; snedecor et al., 2006). paclitaxel 
is an essential drug for the treatment of human cancers. Due to both poor drug solubility and efflux 
systems in the git, peroral delivery of paclitaxel has been a significant challenge (merisko-liversidge, 
2002). A mucoadhesive oral formulation (DHp107™, containing paclitaxel in a mixture of monoolein, 
tricaprylin, and tween 80) has been developed by several researchers (Hong et al., 2007; salles, 2007), 
that can directly and effectively deliver paclitaxel to intestinal endothelial cells without concomitant use 
of p-glycoprotein inhibitors: DHp107 is effectively absorbed through the intestinal lipid transport system, 
by changing spontaneously into droplets smaller than 100-µm and micelles in the intestine, which in 
turn adhere to mucoepithelial cells and is absorbed via lipid uptake mechanism, forming subsequently 
lipid bodies in the epithelium (Hong et al., 2007; salles, 2007).
3.3. solEMuls® tECHNology
Different methods can be approached to formulate poorly water soluble drugs, including use of solvent 
mixtures, surfactants for solubilisation, partial combination of surfactants and solvent mixtures, mixed 
micelles, and o/w emulsions (muller, 2001; muller et al., 2004; boyd et al., 2007). However, for many poorly 
soluble drugs of interest no mixtures of water-organic solvent are available providing sufficiently high 
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emulsions, is dissolution of both lecithin and the drug in an organic solvent, removal of the solvent by 
evaporation, and using the remaining lecithin-drug mixture for emulsion production (lance et al., 1995; 
junghanns et al., 2007). However, this process is not production-friendly, not suitable for sterile pro-
duction, and is also costly. thus, a novel approach has been described: solubilisation by emulsification 
(solemuls® technology) (Akkar and muller, 2003a,b; junghanns et al., 2007). this process can in principle 
be applied to all poorly water-soluble and poorly oil-soluble drugs. Drugs that are poorly soluble in 
both water and oil phases of o/w emulsions can be successfully incorporated into the lecithin layer by 
accelerating the drug crystal dissolution process using high pressure homogenization. the drug dissolu-
tion process can also be performed during production of the emulsion. this approach shows several 
advantages, e.g. no additional excipients are needed in the formulation, the established production 
process of high pressure homogenization can be used without any changes leading to a product of high 
acceptance by the regulatory authorities.
4. conclusions
the issue of poorly soluble drugs and their formulation has attracted increasing attention during the last 
few years. special formulation approaches have been developed, being those of a lipidic nature highly 
suitable for oral drug delivery. nevertheless, absorption of drugs through git is dependent on the nutri-
tional state of the patient and on the presence of bile salts. in general, the presence of lipid molecules 
usually induces secretion of bile salts. the biosensors existing in the duodenum regulate the release of 
bile salts from the gallbladder, independently of the presence of fatty acids and triacylglycerols. secretion 
of lipases from the pancreatic ducts is also regulated. the lipase in combination with co-lipase degrades 
triacylglycerols to surface active mono and diacylglycerols, which can in turn solubilize the drug, thus 
promoting its absorption. Furthermore, mono and diacylglycerols, which can solubilize a poorly soluble 
drug, can form mixed micelles with bile salts, and these mixed micelles promote drug absorption. the li-
pid molecules taken up simultaneously with the drug molecules are absorbed in a kind of a “mechanism 
of absorption promotion effect”. the use of liposomes, lipid nanoparticles and solemuls® technology 
appears to be suitable for oral drug delivery purposes, and to achieve such effect increasing thereafter 
drug bioavailability. the ability of lipid-based drug delivery systems to enhance bioavailability of drug 
molecules that are poorly soluble in water after oral administration, is quite well known, and reflects the 
ability of lipids and their hydrolysis products to interact with endogenous bile salt phospholipid micelles 
in the git, hence resulting in increased solubilization capacity of the gi fluids.
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